ProfileGDS4814 / ILMN_1757306
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 36% 26% 54% 10% 22% 12% 9% 17% 24% 40% 6% 36% 8% 32% 16% 12% 1% 7% 27% 30% 19% 11% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)46.778336
GSM780708Untreated after 4 days (C2_1)44.761726
GSM780709Untreated after 4 days (C3_1)51.944154
GSM780719Untreated after 4 days (C1_2)41.215510
GSM780720Untreated after 4 days (C2_2)44.030722
GSM780721Untreated after 4 days (C3_2)41.61512
GSM780710Trastuzumab treated after 4 days (T1_1)40.85989
GSM780711Trastuzumab treated after 4 days (T2_1)42.798717
GSM780712Trastuzumab treated after 4 days (T3_1)44.379524
GSM780722Trastuzumab treated after 4 days (T1_2)47.754440
GSM780723Trastuzumab treated after 4 days (T2_2)39.8976
GSM780724Trastuzumab treated after 4 days (T3_2)46.777236
GSM780713Pertuzumab treated after 4 days (P1_1)40.56568
GSM780714Pertuzumab treated after 4 days (P2_1)46.014832
GSM780715Pertuzumab treated after 4 days (P3_1)42.635416
GSM780725Pertuzumab treated after 4 days (P1_2)41.71612
GSM780726Pertuzumab treated after 4 days (P2_2)36.32591
GSM780727Pertuzumab treated after 4 days (P3_2)40.3127
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)45.036927
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)45.565230
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)43.292119
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.417411
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)45.698231